Benigne Neoplasien der Orbita

Christoph von Sonnleithner; Malte Zorn; Eckart Bertelmann

doi:10.1055/a-0885-2402

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2019; 236(07): 929-947
DOI: 10.1055/a-0885-2402

CME-Fortbildung

Georg Thieme Verlag KG Stuttgart · New York

Benigne Neoplasien der Orbita

Benign Neoplasms of the Orbit

Autoren

Christoph von Sonnleithner
Malte Zorn
Eckart Bertelmann

Abstract

Zusammenfassung

Die Vielfalt orbitaler Raumforderungen ist außerordentlich groß. Manche Entitäten sind sehr selten. Das häufigste Symptom ist der Exophthalmus, daneben können Bulbusdislokation, Strabismus, Schmerzen, Sehverschlechterung und Gesichtsfeldausfälle auftreten. Die Therapie der Wahl bei den meisten symptomatischen benignen Neoplasien der Orbita ist die chirurgische Resektion.

Abstract

Benign orbital neoplasms comprise a wide spectrum of different entities. The origin of the tumours can be epithelial or mesenchymal. Epithelial neoplasms of the orbit originate from the lacrimal gland. The most important tumour is the pleomorphic adenoma, which should not be biopsied but resected in toto. The most common intraconal neoplasm in adults is the cavernous hemangioma. Symptomatic cavernous hemangiomas should be treated. The treatment of choice for most symptomatic benign neoplasms of the orbit is surgical resection. Suitable surgical approaches are anterior transconjunctival and lateral orbitotomy. Cryoextraction is a minimally invasive technique that is particularly suitable for cavernous hemangiomas.

Schlüsselwörter

gutartige Orbitaneoplasien - pleomorphes Adenom - orbitales Hämangiom - Dermoidzyste

Key words

orbital masses - pleomorphic adenoma - orbital hemangioma - dermoid cyst

Volltext

Referenzen

Literatur
1 Riede UN, Schaefer HE, Wehner H. Allgemeine und spezielle Pathologie. 2. Aufl.. Stuttgart: Thieme; 1989
2 Ro SR, Asbach P, Siebert E. et al. Characterization of orbital masses by multiparametric MRI. Eur J Radiol 2016; 85: 324-336
3 Erb-Eigner K, Asbach P, Ro SR. et al. DCE-MR imaging of orbital lesions: diagnostic performance of the tumor flow residence time τ calculated by a multi-compartmental pharmacokinetic tumor model based on individual factors. Acta Radiol 2018;
4 Sahlmüller M, Schroeter J. Idiopathic inflammatory orbitopathy. Klin Monbl Augenheilkd 2011; 228: 827-840 quiz 841–842 doi:10.1055/s-0031-1280222
5 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T. et al. Propranolol for severe haemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651
6 Avigitidou G, Koch RK, Cursiefen C. et al. Current aspects of eyelid, lacrimal and orbital surgery in childhood. Ophthalmologe 2015; 112: 102-109
7 Sherman RP, Rootman J, Lapointe JS. Orbital dermoids: clinical presentation and management. Br J Ophthalmol 1984; 68: 642-652
8 Cavazza S, Laffi GL, Lodi L. et al. Orbital Dermoid Cyst of Childhood: Clinical Pathologic Findings, Classification and Management. Int Ophthalmol 2011; 31: 93-97
9 Shields CL, Shields JA. Lacrimal gland tumors. Int Ophthalmol Clin 1993; 33: 181-188
10 Rose GE, Wright JE. Pleomorphic adenoma of the lacrimal gland. Br J Ophthalmol 1992; 76: 395-400
11 Lai T, Prabhakaran VC, Malhotra R. et al. Pleomorphic adenoma of the lacrimal gland: is there a role for biopsy?. Eye (Lond) 2009; 23: 2-6
12 Bertelmann E, Minko N. Safety of the preoperative evaluation of pleomorphic adenoma: a retrospective analysis. Klin Monatsbl Augenheilkd 2012; 229: 231-235
13 Fletcher CDM. Diagnostic Histopathology of Tumors. London: Churchill Livingston Elsevier; 2007
14 Shields JA, Shields CL, Scartozzi R. . Survey of 1264 patients with orbital tumors and simulating lesions. Ophthalmology 2004; 111: 997-1008
15 Chandrasekhar J, Farr DR, Whear NM. Pleomorphic adenoma of the lacrimal gland: case report. Br J Oral Maxillofac Surg 2001; 39: 390-393
16 Iyeyasu J, Reis F, Altemani A. et al. An unusual presentation of lacrimal gland pleomorphic adenoma. Rev Bras Oftalmol 2013; 72: 338-340
17 Aghaghazvini L, Salahshour F, Yazdani N. et al. Dynamic contrast-enhanced MRI for differentiation of major salivary glands neoplasms, a 3-T MRI study. Dentomaxillofac Radiol 2015; 44: 20140166
18 Zheng N, Li R, Liu W. et al. The diagnostic value of combining conventional, diffusion-weighted imaging and dynamic contrast-enhanced MRI for salivary gland tumours. Br J Radiol 2018; 91: 20170707
19 Eida S, Sumi M, Sakihama N. et al. Apparent diffusion coefficient mapping of salivary gland tumors: prediction of the benignancy and malignancy. AJNR Am J Neuroradiol 2007; 28: 116-121
20 Assili S, Fathi Kazerooni A, Aghaghazvini L. et al. Dynamic contrast magnetic resonance imaging (DCE-MRI) and diffusion weighted MR imaging (DWI) for differentiation between benign and malignant salivary gland tumors. J Biomed Phys Eng 2015; 5: 157-168
21 Font RL, Gamel JW. Epithelial Tumors of the lacrimal Gland: an Analysis of 265 Cases. In: Jakobiec FA. ed. Ocular and adnexal Tumors. Birmingham, AL: Aesclulapius Publishers Inc; 1978: 787-805
22 Wright JE, Steward WB, Krohel GB. Clinical presentation and management of lacrimal gland tumors. Br J Ophthalmol 1979; 63: 600-606
23 Wright JE. Factors affecting the survival of patients with lacrimal gland tumors. Can J Ophthalmol 1982; 17: 3-9
24 Mensink HW, Mooy CM, Paridaens D. In situ adenocarcinoma ex pleomorphic adenoma of the lacrimal gland. Clin Experiment Ophthalmol 2005; 33: 669-671
25 Currie ZI, Rose GE. Long-term risk of recurrence after intact excision of pleomorphic adenomas of the lacrimal gland. Arch Ophthalmol 2007; 125: 1643-1646
26 Leatherbarrow B. Oculoplastic Surgery. 2nd ed.. ed. London: Informa Healthcare; 2011
27 Tunç M, Sadri E, Char DH. Orbital lymphangioma: an analysis of 26 cases. Br J Ophthalmol 1999; 83: 76-80
28 Graeb DA, Rootman J, Robertson WD. et al. Orbital lymphangiomas: clinical, radiologic and pathologic characteristics. Radiology 1990; 175: 417-421
29 Bond JB, Haik BG, Taveras JL. et al. Magnetic resonance imaging of orbital lymphangioma with and without gadolinium contrast enhancement. Ophthalmology 1992; 99: 1318-1324
30 Suzuki Y, Obana A, Lohto Y. et al. Management of orbital lymphangioma using intralesional injection of OK-432. Br J Ophthalmol 2000; 84: 614-617
31 Poonyathalang A, Preechawat P, Jiarakongmun P. et al. Sclerosing therapy for orbital lymphangioma using sodium tetradecyl sulfate. Jpn J Ophthalmol 2008; 52: 298-304
32 Wojno TH. Sotradecol (sodium tetradecyl sulfate) injection of orbital lymphangioma. Ophthal Plast Reconstr Surg 1999; 15: 432-437
33 Boulos PR, Harissi-Dagher M, Kavalec C. et al. Intralesional injection of Tisseel fibrin glue for resection of lymphangioma and other thin walled orbital cysts. Ophthalmic Plast Reconstr Surg 2005; 21: 171-176
34 Deparis SW, Goldberg AN, Indaram M. et al. Paranasal sinus mucocele as a late complication of dacryocystorhinostomy. Ophthal Plast Reconstr Surg 2017; 33 (3S Suppl 1): S23-S24
35 Sheyn A, Naylor T, Lenes-voit F. et al. Maxillary sinus mucoceles and other side effects ofexternal-beam radiation in the pediatric patient: A cautionary tale. Ear Nose Throat J 2017; 96: E27-E28
36 Scangas GA, Gudis DA, Kennedy DW. The natural history and clinical characteristics of paranasal sinus mucoceles: a clinical review. Int Forum Allergy Rhinol 2013; 3: 712-717
37 Prendes MA, Perszyk I, Horkey D. et al. Isolated orbital mucoceles in the absence of obstructive sinus disease. Orbit 2017; 36 (06) 388-391
38 Devars du Mayne M, Moya-Plana A, Malinvaud D. et al. Sinus mucocele: natural history and long-term recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis 2012; 129: 125-130
39 Tailor R, Obi E, Burns J. et al. Fronto-orbital mucocele and orbital involvement in occult obstructive frontal sinus disease. Br J Ophthalmol 2016; 100: 525-530
40 Carroll GS, Haik BG, Fleming JC. et al. Peripheral nerve tumors of the orbit. Radiol Clin North Am 1999; 37: 195-202 xi–xii
41 Rootman J, Goldberg C, Robertson W. Primary orbital schwannomas. Br J Ophthalmol 1982; 66: 194-204
42 Zhang ML, Suarez MJ, Bosley TM. et al. Clinicopathologic features of peripheral nerve sheath tumors involving the eye and ocular adnexa. Hum Pathol 2017; 63: 70-78
43 Wang Y, Xiao LH. Orbital schwannomas: findings from magnetic resonance imaging in 62 cases. Eye (Lond) 2008; 22: 1034-1039
44 Lee LR, Gigantelli JW, Kincaid MC. Localized neurofibroma of the orbit: a radiographic and histopathologic study. Ophthal Plast Reconstr Surg 2000; 16: 241-246
45 Karcioglu Z. Clinicopathologic Correlates in orbital Disease. Duaneʼs Foundations of clinical Ophthalmology, Vol. 3, Chapter 17. Philadelphia: Lippincott Williams & Wilkins; 2006
46 Misra S, Gogri P, Misra N. et al. Recurrent neurofibroma of the orbit. Australas Med J 2013; 6: 189-191
47 Van Zuuren EJ, Posma AN. Diffuse neurofibroma on the lower back. J Am Acad Dermatol 2003; 48: 938-940
48 Kumar BS, Gopal M, Talwar A. et al. Diffuse neurofibroma of the scalp presenting as circumscribed alopecic patch. Int J Trichology 2010; 2: 60-62
49 Falzon K, Drimitzas E, Picton S. et al. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Br J Ophthalmol 2018; 102: 1367-1371 doi:10.1136/bjophthalmol-2017-311305
50 Wilhelm H. Meningeome im Bereich der vorderen Sehbahn. Ophthalmologe 2013; 110 (05) 403-407
51 Haroche J, Cohen-Aubart F, Emile JF. et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol 2015; 33: 411-418
52 Heisig A, Sörensen J, Zimmermann SY. et al. Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. Oncotarget 2018; 9: 22236-22240
53 Faber W, Kock E, Landau I. et al. Trochleanahes Chondrom der Orbita. Klin Monatsbl Augenheilkd 1992; 200: 138-139 doi:10.1055/s-2008-1045727